Immuno-oncology drug development forges on despite COVID-19

Nature Reviews Drug Discovery, Published online: 18 September 2020; doi:10.1038/d41573-020-00166-1Immuno-oncology drug development forges on despite COVID-19

3d

Immuno-oncology drug development forges on despite COVID-19

3d

Selectively triggering mitotic failure

Nature Reviews Drug Discovery, Published online: 17 September 2020; doi:10.1038/d41573-020-00165-2Selectively triggering mitotic failure

4d

Selectively triggering mitotic failure

4d

Targeting co-stimulatory molecules in autoimmune disease

Nature Reviews Drug Discovery, Published online: 16 September 2020; doi:10.1038/s41573-020-0081-9Immune activating antibodies that target co-stimulatory molecules have altered the cancer therapy landscape. Here, Walker and colleagues discuss therapies — particularly those that target molecules in the same families as CTLA4 and PD1 or TNF receptor —...

5d

Targeting co-stimulatory molecules in autoimmune disease

5d

Targeting the epigenetic regulation of antitumour immunity

Nature Reviews Drug Discovery, Published online: 14 September 2020; doi:10.1038/s41573-020-0077-5Aberrant epigenetic processes can influence tumour immunogenicity and immune cells involved in the response to cancer. This Review highlights how epigenetic regulators can be modulated with small-molecule drugs to promote antitumour immune responses, and...

1w

Targeting the epigenetic regulation of antitumour immunity

1w

Trispecific antibodies take to the clinic

Nature Reviews Drug Discovery, Published online: 11 September 2020; doi:10.1038/d41573-020-00164-3Sanofi and others are testing whether trispecific antibodies might have applications in cancer and infectious disease indications.

2w

Karen Akinsanya

Nature Reviews Drug Discovery, Published online: 11 September 2020; doi:10.1038/d41573-020-00162-5Computational chemistry is already embedded in the drug discovery process. Schrödinger — a company that was founded more than 30 years ago to develop chemical simulation software for biopharmaceutical partners — believes that it should be more foundational...

2w